Malin Corporation PLC
ISEQ:MLC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.2), the stock would be worth €8.2 (3% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | €7.95 |
0%
|
| 3-Year Average | 0.2 | €8.2 |
+3%
|
| 5-Year Average | 0.1 | €4.95 |
-38%
|
| Industry Average | 1.5 | €66.65 |
+738%
|
| Country Average | 1.5 | €66.65 |
+738%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
M
|
Malin Corporation PLC
ISEQ:MLC
|
34.4m EUR | 0.2 | 0 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 132.2 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.4 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 2.4 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 4.2 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 3.8 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.7 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 11.5 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 4.2 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | -1 087.5 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.8 |
| Median | 1.5 |
| 70th Percentile | 2.6 |
| Max | 22.9 |
Other Multiples
Malin Corporation PLC
Glance View
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.
